Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

[Vaccination against hepatitis. Present and future].

R Rüger, B Fleckenstein

    Fortschritte Der Medizin
    |April 7, 1983
    PubMed
    Summary
    This summary is machine-generated.

    Related Concept Videos

    You might also read

    Related Articles

    Articles linked to this work by shared authors, journal, and citation graph.

    Sort by
    Same author

    Use of Density Functional Based Tight Binding Methods in Vibrational Circular Dichroism.

    The journal of physical chemistry. A·2018
    Same author

    Clinically significant CMV (re)activation during or after radiotherapy/chemotherapy of the brain : Correlation with neurological deterioration and improvement upon antiviral treatment.

    Strahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft ... [et al]·2016
    Same author

    Loss-of-function mutations within the IL-2 inducible kinase ITK in patients with EBV-associated lymphoproliferative diseases.

    Leukemia·2012
    Same author

    Nonradioactive labeling of polymerase chain reaction products.

    Methods in molecular biology (Clifton, N.J.)·2011
    Same author

    [The German Excellence Initiative : effects on the medical schools].

    Bundesgesundheitsblatt, Gesundheitsforschung, Gesundheitsschutz·2009
    Same author

    The monoclonal antibody 6B9 recognizes CD44 and not cell surface transglutaminase 2.

    Scandinavian journal of immunology·2008

    Hepatitis A and B vaccines are advancing, with inactivated and attenuated strains for Hepatitis A and a safe HBsAg vaccine for Hepatitis B. Future Hepatitis B vaccines utilize genetic engineering, while non-A-non-B hepatitis prevention remains elusive due to unknown causative agents.

    Area of Science:

    • Virology
    • Immunology
    • Vaccinology

    Context:

    • Hepatitis A virus (HAV), a picornavirus, is now cultured in vitro.
    • Hepatitis B virus (HBV) is the prototype hepadnavirus.
    • The etiology of non-A-non-B hepatitis remains unidentified.

    Purpose:

    • To review the current status and future directions of vaccine development for Hepatitis A, Hepatitis B, and non-A-non-B hepatitis.
    • To highlight advancements in vaccine technology, including inactivated, attenuated, and genetically engineered vaccines.

    Summary:

    • Hepatitis A vaccines, including inactivated and attenuated forms, are in early field use.
    • A safe and effective Hepatitis B vaccine, based on the Hepatitis B surface antigen (HBsAg), is available.
    • Future Hepatitis B vaccines will leverage genetic engineering for in vitro synthesis of oligopeptides or cloned viral DNA expression.

    Related Experiment Videos

  • Immunoprevention for non-A-non-B hepatitis is currently not feasible due to the unknown nature of the causative agents.

    • Impact:

    • Provides an overview of current and emerging hepatitis vaccine strategies.
    • Underscores the progress in combating Hepatitis A and B through vaccination.
    • Identifies the significant challenge posed by non-A-non-B hepatitis and the need for etiological identification for prevention.